Meet with... Johnson & Johnson Innovation

Add this event to your calendar:
25/03/2015 12:30 25/03/2015 14:30 America/New_York Meet with... Johnson & Johnson Innovation JLABS @LabCentral , 700 Main St , Cambridge , MA 02139 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
March
25
Event

Meet with... Johnson & Johnson Innovation

JLABS @LabCentral , 700 Main St , Cambridge , MA 02139

March 25, 2015 from 12:30 PM to 14:30 PM (EDT)

$10 - $35


JLABS BOSTON EVENT How can Johnson & Johnson Innovation help you reach your goals? Johnson & Johnson Innovation (JJI) is supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS (JLABS), with the ultimate aim of enabling commercialization of new healthcare solutions for patients. We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The JJI team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.

Our corporate venture group, Johnson & Johnson Development Corporation (JJDC), can also fund great science in a more traditional way. Together, our teams can provide you the best possible chance of taking your solution to the people who need it the most.

On March 25, hear from folks on all sides of Johnson & Johnson Innovation: platform innovation, new ventures, pharmaceutical, consumer, and medical device, and JJDC. These experts will provide an overview of JJI goals and mission, highlighting how JJI interacts with the entrepreneurial community through JLABS, JJDC, and other JJI initiatives. Don't miss this opportunity to learn more on the progress of this groundbreaking project.

Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.

Agenda:
11:30am | Registration and Lunch
12:00pm | Presentation and Q&A
1:30-4:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on March 4th.

Johnson & Johnson Innovation (JJI) Participating Representatives:
Ibraheem Badejo, Ph.D. | Sr. Director, New Ventures, JJI read bio»
Michelle F. Browner, Ph.D. | Platform Innovation & Partnership Management, JJI read bio»
Kate Luedtke | Associate Director, External Innovation, Johnson & Johnson Consumer and Personal Products read bio»
Tom Luby | Sr. Director, New Ventures, JJI read bio»
Marian Nakada, Ph.D. | Vice President, Venture Investments, JJDC read bio»

Fees:
Presentation & Lunch
FREE | General Public
FREE | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must register for the presentation, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until March 24th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on March 4th. Your application will be reviewed and you will be notified of acceptance by March 16th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Venue:
JLABS @LabCentral
700 Main St
Cambridge, MA 02139

Johnson & Johnson Innovation (JJI) Participating Representatives' Biographies:
Ibraheem Badejo Ibraheem Badejo, Ph.D. | Sr. Director, New Ventures, JJI
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.
From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.
During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.
Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.

Connect with Ibraheem: Connect on LinkedIn    




Michelle Browner Michelle F. Browner, Ph.D. | Platform Innovation & Partnership Management, JJI
Michelle is Senior Director of Platform Innovation and Partnership Management at Johnson & Johnson Innovation, Boston.
Previously Michelle was CEO of Enlight Biosciences, a unique entrepreneurial partnership with major pharmaceutical companies and leading academic researchers, focused on building companies based on breakthrough innovations for drug discovery and development.
Michelle had a distinguished career at Roche Pharmaceuticals, where she was the Global Head of Emerging Science and Technologies in Pharma Partnering, Basel, Switzerland from 2010 to 2011. She served as the Global Head of Pharma Research Strategy, responsible for creating and implementing a strategic plan for the global research organization, from 2007-2010.
Michelle joined Roche in 1993, rising to the position of Vice President of Discovery Technologies in Palo Alto, California. She contributed to drug discovery projects in the disease areas of inflammation and virology, advancing more than a dozen compounds to clinical trials, with several progressing towards commercial development. She led the way in implementing cutting edge technologies for lead discovery of small and large molecules; including establishing structure-based drug discovery, high-throughput crystallography and fragment-based screening.
Michelle earned her PhD in Cell Biology from Baylor College of Medicine after graduating with high honors in Biology from Kenyon College. She has an international scientific reputation in drug discovery and structural biology with over 45 publications.

Connect with Michelle: Connect on LinkedIn Connect on Twitter  




Kate Luedtke | Associate Director, External Innovation, Johnson & Johnson Consumer and Personal Products
Kate Luedtke is Associate Director, External Innovation for Johnson & Johnson Consumer and Personal Products Worldwide. She is currently leading a cross-franchise innovation platform focused on functional fragrances & flavors. She has held various R&D and marketing roles since joining Johnson & Johnson in 2001 and has a proven track record of coupling innovation with consumer insights to drive business results.
Kate received a BS degree in chemical engineering from Princeton University and MBA from Temple University. She is co-inventor of several patents and was the recipient of the Johnson's Medal in 2008 for her work in developing JOHNSON'S® baby BEDTIME® routine.

Connect with Kate: Connect on LinkedIn    




Tom Luby Tom Luby | Sr. Director, New Ventures, JJI
Tom is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston. He focuses primarily on cardiovascular & metabolic; infectious diseases and Vaccines; and neurobiology.
Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies. In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the BOD at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture.
Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech. He has worked on multiple discovery through Phase II programs in infectious disease, oncology, immunotherapy, and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach.
Tom received his BS in Biology from State University of New York, his PhD in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.

Connect with Tom: Connect on LinkedIn    




Marian Nakada Marian Nakada, Ph.D. | Vice President, Venture Investments, JJDC
Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston. She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics.
Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.
Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry.
Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.

Connect with Marian: Connect on LinkedIn Connect on Twitter  





About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Poliwogg, and OrbiMed.


Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content